Methylergonovine is used to prevent or treat bleeding from the uterus that can happen after childbirth or an abortion.
methylergometrine
methylergometrine injection
Methylergonovine Maleate Injection is a semi-synthetic ergot alkaloid used for the prevention and control of postpartum hemorrhage. Here are the details:
Description:
Methylergonovine Maleate Injection, USP, is available in sterile ampules of 1 mL, containing 0.2 mg methylergonovine maleate for intramuscular or intravenous injection.
The ampules contain a clear, colorless solution.
Active Ingredient: methylergonovine maleate, USP, 0.2 mg.
Inactive Ingredients: maleic acid (0.10 mg), sodium chloride (7.0 mg), and water for injection (qs to 1 mL).
Chemically, methylergonovine maleate is designated as ergoline-8-carboxamide, 9,10-didehydro-N-[l-(hydroxymethyl)propyl]-6-methyl-, [8β(S)]-, (Z)-2-butenedioate (1:1) (salt).
Clinical Pharmacology:
Methylergonovine maleate acts directly on the smooth muscle of the uterus, increasing the tone, rate, and amplitude of rhythmic contractions.
It induces a rapid and sustained tetanic uterotonic effect, shortening the third stage of labor and reducing blood loss.
The onset of action after intravenous (I.V.) administration is immediate, after intramuscular (I.M.) administration is 2-5 minutes, and after oral administration is 5-10 minutes.
Pharmacokinetic studies show rapid distribution from plasma to peripheral tissues within 2-3 minutes or less after I.V. injection.
Bioavailability after oral administration is about 60%, with no accumulation after repeated doses.
During delivery with I.M. injection, bioavailability increases to 78%.
Remember to consult a healthcare professional for personalized advice regarding the use of Methylergonovine Maleate Injection. If you have any further questions or need additional information, feel free to ask! 😊
For more detailed information, you can refer to the official prescribing information